Literature DB >> 9875554

Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2.

H Suzuki1, Y Sugiyama.   

Abstract

It has been shown that both multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (cMOAT/MRP2) have the ability to extrude glutathione conjugates (GS-X pump activity)from cells. Therefore, they play an important role in the detoxification of xenobiotics. Using mrp1-knockout mice, it has recently been shown that MRP1/mrp1 has an important role in the export of leukotriene C4 (LTC4), a mediator of inflammation, and in protecting the body from a number of toxins, including several antitumor drugs. A comparison of the transport properties across the bile canalicular membrane in normal and mutant rats, whose cMOAT function is hereditarily defective, has shown that the physiologic role of cMOAT is to excrete LTC4, bilirubin glucuronides, 171-estradiol-170-D-glucuronide, and reduced folates. In the present review article, we summarize the substrate specificity and mechanism for the transport of these GS-X pumps, focusing on the pharmacologic and physiologic aspects. The transport activity mediated by cMOAT is also discussed in terms of a comparison between membrane vesicles from hepatocytes and cMOAT-transfected cells, and we also briefly examine the possible role of MRPI and cMOAT in the extrusion of reduced glutathione.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875554     DOI: 10.1055/s-2007-1007170

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  23 in total

Review 1.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

Review 2.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

3.  Ycf1p attenuates basal level oxidative stress response in Saccharomyces cerevisiae.

Authors:  Christian M Paumi; Kerry A Pickin; Roaa Jarrar; Catherine K Herren; Stuart T Cowley
Journal:  FEBS Lett       Date:  2012-02-23       Impact factor: 4.124

4.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Pharmacokinetic study of the hepatobiliary transport of indomethacin.

Authors:  H Kouzuki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

Review 6.  Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.

Authors:  Kousei Ito; Hiroshi Suzuki; Toshiharu Horie; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

7.  ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling.

Authors:  Yuji Tanaka; Lauren M Aleksunes; Yue Julia Cui; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2009-01-29       Impact factor: 4.849

Review 8.  Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology.

Authors:  Nazzareno Ballatori; Suzanne M Krance; Rosemarie Marchan; Christine L Hammond
Journal:  Mol Aspects Med       Date:  2008-08-26

Review 9.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

10.  Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier.

Authors:  Daisuke Sugiyama; Hiroyuki Kusuhara; Yong-Joo Lee; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.